Paris - Delayed Quote EUR

ABIVAX Société Anonyme (ABVX.PA)

5.17
-0.13
(-2.45%)
As of 9:47:20 AM GMT+2. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Cost of Revenue
--
--
--
50,764
45,517
Gross Profit
--
--
--
-50,764
-45,517
Operating Expense
172,984
172,984
127,377
51,205
41,398
Operating Income
-172,984
-172,984
-127,377
-51,205
-41,398
Net Non Operating Interest Income Expense
-4,564
-4,564
-12,708
-6,717
-3,476
Other Income Expense
1,307
1,307
-7,654
-2,820
2,425
Pretax Income
-176,242
-176,242
-147,740
-60,740
-42,452
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-176,242
-176,242
-147,740
-60,740
-42,452
Diluted NI Available to Com Stockholders
-176,242
-176,242
-147,740
-60,740
-42,452
Basic EPS
-3.43
-2.80
-3.43
-3.18
-2.75
Diluted EPS
-3.43
-2.80
-3.43
-3.18
-2.75
Basic Average Shares
43,066.01
63,046.35
43,066.01
19,092.44
15,455.99
Diluted Average Shares
43,066.01
63,046.35
43,066.01
19,092.44
15,455.99
Total Operating Income as Reported
-172,984
-172,984
-127,376
-64,836
-41,400
Rent Expense Supplemental
482
--
--
1,048
548
Total Expenses
172,984
172,984
127,377
51,205
41,398
Net Income from Continuing & Discontinued Operation
-176,242
-176,242
-147,740
-60,740
-42,452
Normalized Income
-177,549
-177,549
-140,086
-57,920
-44,877
Interest Income
8,956
8,956
2,773
0
0
Interest Expense
12,431
12,431
13,826
6,940
3,558
Net Interest Income
-4,564
-4,564
-12,708
-6,717
-3,476
EBIT
-163,811
-163,811
-133,914
-53,800
-38,894
EBITDA
-162,711
-162,711
-133,207
-53,315
-38,592
Reconciled Cost of Revenue
--
--
--
50,526
45,517
Reconciled Depreciation
1,100
1,100
707
485
302
Net Income from Continuing Operation Net Minority Interest
-176,242
-176,242
-147,740
-60,740
-42,452
Total Unusual Items Excluding Goodwill
1,307
1,307
-7,654
-2,820
2,425
Total Unusual Items
1,307
1,307
-7,654
-2,820
2,425
Normalized EBITDA
-164,018
-164,018
-125,553
-50,495
-41,017
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 6/26/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AYJ.F Valneva SE
2.8040
-2.30%
 
HPHA.DE Heidelberg Pharma AG
3.2700
0.00%
 
VVY.AS Vivoryon Therapeutics N.V.
1.7800
-1.00%
 
SIGHT.PA GenSight Biologics S.A.
0.1998
0.00%
 
ALCLS.PA Cellectis S.A.
1.3300
-0.89%
 
ALSEN.PA Sensorion SA
0.2930
+0.34%
 
PRTCl.XC
 
9LB.MU Legend Biotech Corp
25.60
-2.29%
 
1GDA.F Zevra Therapeutics, Inc.
7.55
+0.67%
 
048410.KQ Hyundai Bioscience Co., Ltd.
11,300.00
+7.52%